Table 1.

Characteristics of Patients in the Analytic Cohort by Case Status

Characteristic	Non–Prostate Cancer		Incident Prostate Cancer
			Total (N = 1,138)		P†	Aggressive* (n = 571)		P†	Nonaggressive* (n = 552)		P†
	No.	%	No.	%		No.	%		No.	%
Randomly assigned group					.032			.013			.801
Usual care	18,143	47.8	581	51.1		303	53.1		267	48.4
Intervention	19,789	52.2	557	48.9		268	46.9		285	51.6
Age at SQX (years)					< .001			.170			< .001
< 65	5,378	14.2	161	14.1		70	12.3		88	15.9
65-69	10,985	29.0	388	34.1		166	29.1		216	39.1
70-74	9,896	26.1	319	28.0		170	29.8		147	26.6
≥ 75	11,673	30.8	270	23.7		165	28.9		101	18.3
Median	71		70			71			69
IQR	66-76		66-74			67-75			66-73
Education					.021			.061			.407
Less than high school	2,211	5.8	45	4.0		20	3.5		23	4.2
High school graduate	11,237	29.6	348	30.6		177	31.0		167	30.3
Some college	7,560	19.9	226	19.9		113	19.8		109	19.7
College graduate	7,661	20.2	212	18.6		104	18.2		107	19.4
Postgraduate	9,173	24.2	305	26.8		156	27.3		146	26.4
Marital status					< .001			.015			< .001
Married or cohabiting	30,888	81.4	978	85.9		488	85.5		478	86.6
Single‡	6,721	17.7	151	13.3		79	13.8		69	12.5
Race					.137			.305			.376
White	33,871	89.3	1,023	89.9		511	89.5		498	90.2
Black	841	2.2	34	3.0		18	3.2		16	2.9
Other§	1,684	4.4	43	3.8		23	4.0		20	3.6
First-degree relative(s) had prostate cancer					< .001			.222			< .001
No	30,129	79.4	853	75.0		438	76.7		402	72.8
Yes	3,297	8.7	138	12.1		57	10.0		80	14.5
Diabetes					.037			.279			< .001
No	27,581	72.7	867	76.2		410	71.8		444	80.4
Yes	6,207	16.4	163	14.3		104	18.2		59	10.7
Myocardial infarction					.008			.257			.005
No	28,137	74.2	875	76.9		427	74.8		438	79.3
Yes	5,343	14.1	129	11.3		70	12.3		56	10.1
Enlarged prostate					< .001			.008			< .001
No	20,710	54.6	510	44.8		280	49.0		220	39.9
Yes	16,889	44.5	619	54.4		286	50.1		328	59.4
BMI at age 50 years (kg/m2)					.036			.126			.265
< 25.0	12,341	32.5	380	33.4		201	35.2		178	32.2
25.0-29.9	17,026	44.9	537	47.2		262	45.9		263	47.6
≥ 30	5,264	13.9	129	11.3		64	11.2		65	11.8
Cigarette smoking					.001			.022			.007
Never	12,999	34.3	442	38.8		220	38.5		220	39.9
Ever	23,771	62.7	659	57.9		329	57.6		317	57.4
Aspirin use frequency					.097			.242			.442
None or < 1 time per month	11,581	30.5	328	28.8		164	28.7		159	28.8
≤ 2 times per week	3,668	9.7	113	9.9		56	9.8		56	10.1
3-6 times per week	3,906	10.3	102	9.0		49	8.6		51	9.2
≥ 7 times per week	17,903	47.2	581	51.1		293	51.3		281	50.9
Male pattern baldness at age 45 years					.368			.119			.981
No baldness	17,678	46.6	522	45.9		257	45.0		260	47.1
Any baldness	20,254	53.4	616	54.1	.750‖	314	55.0	.500‖	292	52.9	.904‖
Frontal baldness only	9,411	24.8	279	24.5		138	24.2		139	25.2
Frontal plus any vertex baldness	9,411	24.8	279	24.5	.625¶	138	24.2	.448¶	139	25.2	.816¶
Frontal plus mild vertex baldness	4,760	12.5	142	12.5		68	11.9		69	12.5
Frontal plus moderate vertex baldness	3,643	9.6	129	11.3		74	13.0		52	9.4
Frontal plus severe vertex baldness	2,440	6.4	66	5.8		34	6.0		32	5.8

NOTE. Column percent may not add up to 100% because of missing data.

Abbreviations: BMI, body mass index; IQR, interquartile range; SQX, supplemental questionnaire.

^*Aggressive prostate cancer was defined as biopsy Gleason score ≥ 7, and/or clinical stage III or greater, and/or prostate cancer as underlying cause of death. Nonaggressive prostate cancer was defined as otherwise. Fifteen prostate cancers lacked enough information to determine prostate cancer subtypes.

^†P values were calculated by Pearson χ² tests by using nonmissing values with comparison to controls without cancer.

^‡Single includes widowed, divorced, separated, and never married.

^§Other race includes Asian, Native Hawaiian or other Pacific Islander, American Indian, or Alaskan Native.

^‖P value was calculated for any baldness and no baldness by Pearson χ² tests compared with controls without cancer.

^¶P value was calculated for frontal baldness only, frontal plus any vertex baldness, and no baldness by Pearson χ² tests compared with controls without cancer.